Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arrowhead Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Today 7:30 EDT
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
August 14, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
August 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
August 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
July 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
June 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
June 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
June 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 31, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
May 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
May 28, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
May 20, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
May 09, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
May 02, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
April 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
April 26, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
April 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
April 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
April 07, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 01, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
March 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
March 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
March 04, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
February 06, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
January 22, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
January 05, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
January 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 29, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
December 21, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.